Volitionrx Ltd (VNRX)
Official siteHEALTHCARE • MEDICAL DEVICES • AMEX
Market Cap: $8.30M
Last updated: Nov 17, 2026 at 11:04 AM ET
Volitionrx Ltd (VNRX) Stock Forecast
Analysts expect Volitionrx (VNRX) to earn -$2.00 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.72M. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 3 | 60.0% |
| Hold | 1 | 20.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 240.8%.
- Fiscal year ending Dec 31, 2026
- -$2.00
- EPS consensus, revenue $2.72M
- Fiscal year ending Dec 31, 2027
- -$0.85
- EPS consensus, revenue $9.27M
- Next report
- Mar 29, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.00 | -$2.00 to -$2.00 | 1 | $2.72M | $2.33M to $3.50M | 5 |
| Dec 31, 2027 | -$0.85 | -$0.85 to -$0.85 | 1 | $9.27M | $3.50M to $21.30M | 4 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.29 | -$0.37 to -$0.20 | 7 | $696150 | $470400 to $997500 | 7 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.60.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.00 | -$2.62 | -$2.62 | -$2.62 | -$2.60 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.85 | -$1.15 | -$1.15 | -$1.15 | $10.80 | N/A |
Frequently Asked Questions About VNRX
What is the VNRX stock forecast?
Consensus analyst estimates put Volitionrx's EPS at -$2.00 for the fiscal year ending Dec 31, 2026, on revenue of $2.72M. The consensus rating from 5 analysts is Buy.
How do analysts rate VNRX stock?
Of 5 analysts covering Volitionrx, 1 rates it Strong Buy, 3 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VNRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.00, with estimates from -$2.00 to -$2.00 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.85, with estimates from -$0.85 to -$0.85 from 1 analyst.
What revenue do analysts expect from Volitionrx next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.72M, with estimates from $2.33M to $3.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $9.27M, with estimates from $3.50M to $21.30M.
How many analysts cover VNRX?
5 analysts rate Volitionrx stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
VNRX pages: Overview, Earnings, Forecast, Financials, Competitors